The new drug TQA3605 for hepatitis B virus achieved the primary endpoint in phase II clinical trials.

On January 27th, China Biologic Pharmaceutical's subsidiary, Zhongda Tianqing, announced that its oral type 1 new drug for chronic hepatitis B virus infection the core protein conformational regulator TQA3605, has successfully reached the primary endpoint in Phase II clinical trials. After 24 weeks of treatment with nucleoside drugs in all dosage groups of TQA3605, nearly 90% of the subjects had HBV DNA levels below the lower limit of quantification.